Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 168 of 168 results for fibrosis

  1. NICE responds to failure of talks to reach price agreement on Enhertu

    Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.

    News
    Last updated
    19 November 2024

  2. NICE recommended a new gene therapy, transformative cystic fibrosis medicines and an obesity jab, during election period

    More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.

    News
    Last updated
    10 July 2024

  3. NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

    Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.

    News
    Last updated
    29 July 2024